Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC）
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug
Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing
Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with
multi-targets, especially for VEGFR2、VEGFR3、PDGFRβ and c-Kit. It has the obvious resistance
to new angiogenesis. The trial is to compare the efficacy and safety profile between
Anlotinib and Sunitinib in patients with advanced Renal Cell Carcinoma(RCC).
Phase:
Phase 2
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd